公开(公告)号：US20080147178A1

公开(公告)日：2008-06-19

申请号：US11942693

申请日：2007-11-19

Applicant: Stephen Pacetti ,  Wouter Roorda

Inventor： Stephen Pacetti ,  Wouter Roorda

IPC: A61F2/82 ,  A61M25/10 ,  A61K47/32 ,  C08F218/02 ,  A61B17/00

CPC classification number: A61L27/54 ,  A61L27/34 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/00 ,  C08L27/18

Abstract: Biocompatible copolymers are manufactured to include a zwitterionic monomer and an alkoxy acrylate monomer. The alkoxy acrylate monomer can be a 2-methoxyethyl methacrylate (MOEMA) or a 2-methoxyethyl methacrylate (EOEMA). Alternatively, the alkoxy acrylate can be 2-methoxyethyl acrylate (MOEA) or 2-ethoxyethyl acrylate (EOEA). The alkoxy acrylate monomers advantageously give the zwitterionic copolymers greater ductility, strength, and toughness while maintaining a desired amount of hydrophilicity. The improved toughness allows the zwitterionic copolymers to be processed without cross-linking, which improves the elongation properties of the zwitterionic copolymer, and reduces the risk of cracking during use.

Abstract translation: 制造生物相容性共聚物以包括两性离子单体和烷氧基丙烯酸酯单体。 烷氧基丙烯酸酯单体可以是甲基丙烯酸2-甲氧基乙酯（MOEMA）或甲基丙烯酸2-甲氧基乙酯（EOEMA）。 或者，烷氧基丙烯酸酯可以是丙烯酸2-甲氧基乙酯（MOEA）或丙烯酸2-乙氧基乙酯（EOEA）。 烷氧基丙烯酸酯单体有利地使两性离子共聚物具有更高的延展性，强度和韧性，同时保持所需量的亲水性。 改进的韧性使得两性离子共聚物在不交联的情况下进行加工，这提高了两性离子共聚物的伸长性能，并降低了使用过程中的开裂风险。

公开(公告)号：US20050142202A1

公开(公告)日：2005-06-30

申请号：US11015943

申请日：2004-12-17

Applicant: Wouter Roorda ,  Stephen Pacetti

Inventor： Wouter Roorda ,  Stephen Pacetti

IPC: A61K9/16 ,  A61K31/727 ,  A61K48/00 ,  A61K9/14 ,  A61K38/18

CPC classification number: A61K9/14 ,  A61K9/1617 ,  A61K9/1647 ,  A61K9/1658 ,  A61K9/1694 ,  A61K31/573 ,  A61K31/727 ,  A61K38/1825 ,  A61K47/26 ,  A61K47/36 ,  A61K48/00

Abstract: Compositions and methods of using the compositions to achieve a therapeutic effect are provided.

Abstract translation: 提供了使组合物达到治疗效果的组合物和方法。

公开(公告)号：US20090286761A1

公开(公告)日：2009-11-19

申请号：US12191209

申请日：2008-08-13

Applicant: Jin Cheng ,  Stephen Dugan ,  Gordon Stewart ,  Gina Zhang ,  Nancy Kirsten ,  Paul Consigny ,  Christopher Feezor ,  Gene Park ,  Wouter Roorda ,  Syed F.A. Hossainy

Inventor： Jin Cheng ,  Stephen Dugan ,  Gordon Stewart ,  Gina Zhang ,  Nancy Kirsten ,  Paul Consigny ,  Christopher Feezor ,  Gene Park ,  Wouter Roorda ,  Syed F.A. Hossainy

IPC: A61K31/56 ,  A61P7/00

CPC classification number: A61L31/16 ,  A61F2/91 ,  A61F2250/0067 ,  A61F2250/0068 ,  A61K31/4745 ,  A61K31/56 ,  A61K31/573 ,  A61L31/10 ,  A61L31/148 ,  A61L2300/222 ,  A61L2300/416 ,  A61L2300/45 ,  A61K2300/00

Abstract: A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 μg, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).

Abstract translation: 提供了一种药物递送系统，其包括至少100杯依维莫司和氯倍他索，使得依维莫司与氯倍他索的比例至少为10：1（w / w），依维莫司的重量比为至少10倍 氯倍他索 该系统可以是支架。 还提供了治疗血管的再狭窄或易损斑块的方法，所述方法包括向患者局部施用选自雷帕霉素（西罗莫司），Biolimus A9，deforolimus，AP23572，他克莫司，替西罗莫司，吡美莫司， 40-（2-羟基）乙基雷帕霉素（依维莫司），40-O-（3-羟基）丙基雷帕霉素，40-O- [2-（2-羟基）乙氧基]乙基雷帕霉素，40- O-四唑基雷帕霉素和40-表 - （N1-四唑基）雷帕霉素，并且对患者局部施用由氯倍他索组成的第二药物，其中局部施用的第一药物的最小量为100杯，其中 第二种药物的第一种药物例如为10：1〜100：1（w / w）。

公开(公告)号：US20080124372A1

公开(公告)日：2008-05-29

申请号：US11448956

申请日：2006-06-06

Applicant: Syed F. A. Hossainy ,  Fuh-Wei Tang ,  Lothar Kleiner ,  Thierry Glauser ,  Yiwen Tang ,  Wouter Roorda ,  Stephen Pacetti ,  Gina Zhang ,  Yung-Ming Chen ,  Andrew F. McNiven ,  Sean A. McNiven ,  Brandon J. Yoe

Inventor： Syed F. A. Hossainy ,  Fuh-Wei Tang ,  Lothar Kleiner ,  Thierry Glauser ,  Yiwen Tang ,  Wouter Roorda ,  Stephen Pacetti ,  Gina Zhang ,  Yung-Ming Chen ,  Andrew F. McNiven ,  Sean A. McNiven ,  Brandon J. Yoe

IPC: A61F2/06 ,  B05D3/00 ,  A61K47/48 ,  A61K31/436 ,  A61K31/337 ,  A61K31/46 ,  A61P9/00

CPC classification number: A61L31/10 ,  A61L27/40 ,  A61L27/44 ,  A61L27/50 ,  A61L27/54 ,  A61L31/12 ,  A61L31/14 ,  A61L31/16 ,  A61L2300/00

Abstract: The present disclosure teaches methods of controlling the release rate of agents from a polymeric matrix that include designing and creating a predetermined initial morphology (IM) profile in a polymeric matrix. The teachings indicate, inter alia, that control over the release rate of agents can provide for an improved control over the administration of agents as well as have an effect upon the mechanical integrity and absorption rate of the polymeric matrix.

Abstract translation: 本公开教导了控制来自聚合物基质的试剂的释放速率的方法，其包括在聚合物基质中设计和产生预定的初始形态（IM）分布。 教导尤其表明，对药剂释放速率的控制可以提供对药剂施用的改进控制，以及对聚合物基质的机械完整性和吸收速率的影响。

公开(公告)号：US20050106203A1

公开(公告)日：2005-05-19

申请号：US10176504

申请日：2002-06-21

Applicant: Wouter Roorda ,  Ni Ding ,  Stephen Pacetti ,  Eugene Michal ,  Ashok Shah ,  Syed Hossainy

Inventor： Wouter Roorda ,  Ni Ding ,  Stephen Pacetti ,  Eugene Michal ,  Ashok Shah ,  Syed Hossainy

IPC: A61L31/00 ,  A61F2/84 ,  A61K31/436 ,  A61L27/34 ,  A61L31/10 ,  A61L31/16 ,  A61K47/32

CPC classification number: A61L31/16 ,  A61L31/10 ,  A61L2300/416 ,  A61L2300/602 ,  A61L2300/606 ,  A61L2300/608 ,  A61L2420/08 ,  C08L33/10 ,  C08L33/06

Abstract: A coating for a medical device, particularly for a drug eluting stent, is described. The coating can include a polyacrylate, a blend of polyacrylates, or a blend of the polyacrylate with other polymers, for example, poly(ethylene-co-vinyl alcohol).

Abstract translation: 描述了用于医疗装置的涂层，特别是用于药物洗脱支架的涂层。 涂层可以包括聚丙烯酸酯，聚丙烯酸酯的共混物或聚丙烯酸酯与其它聚合物的共混物，例如聚（乙烯 - 共 - 乙烯醇）。

公开(公告)号：US09248121B2

公开(公告)日：2016-02-02

申请号：US11839093

申请日：2007-08-15

Applicant: Wouter Roorda

Inventor： Wouter Roorda

IPC: A61K31/436 ,  A61K9/00 ,  A61L31/14 ,  A61L31/16

CPC classification number: A61K31/436 ,  A61F2250/0067 ,  A61F2250/0068 ,  A61L31/10 ,  A61L31/146 ,  A61L31/16 ,  A61L2300/608 ,  B22F3/008 ,  B22F3/105 ,  B22F2003/1051 ,  B22F2003/1054

Abstract: The present invention is a medical device for controlling the release of an active agent. The medical device has a supporting structure having a porous body disposed therein. At least one elution rate controlling matrix containing an effective amount of at least one active agent is disposed within the pores of the porous body in a manner that protects the matrix from mechanical damage. The medical device may therefore be used for controlled drug release applications. Additionally, the present invention discloses a method for using the medical device for the treatment and prevention of diseases in mammals. This invention further relates to a method for using the medical device for treating and preventing vascular diseases.

Abstract translation: 本发明是用于控制活性剂释放的医疗装置。 医疗器具具有设置在其中的多孔体的支撑结构。 含有有效量的至少一种活性剂的至少一种洗脱速率控制基质以保护基质免受机械损伤的方式设置在多孔体的孔内。 因此，医疗装置可以用于受控药物释放应用。 另外，本发明公开了一种使用该医疗装置来治疗和预防哺乳动物疾病的方法。 本发明还涉及一种用于治疗和预防血管疾病的医疗装置的方法。

公开(公告)号：US08435550B2

公开(公告)日：2013-05-07

申请号：US12191209

申请日：2008-08-13

Applicant: Jin Cheng ,  Stephen Dugan ,  Gordon Stewart ,  Gina Zhang ,  Nancy Kirsten ,  Paul Consigny ,  Christopher Feezor ,  Gene Park ,  Wouter Roorda ,  Syed F. A. Hossainy

Inventor： Jin Cheng ,  Stephen Dugan ,  Gordon Stewart ,  Gina Zhang ,  Nancy Kirsten ,  Paul Consigny ,  Christopher Feezor ,  Gene Park ,  Wouter Roorda ,  Syed F. A. Hossainy

IPC: A61F2/02

CPC classification number: A61L31/16 ,  A61F2/91 ,  A61F2250/0067 ,  A61F2250/0068 ,  A61K31/4745 ,  A61K31/56 ,  A61K31/573 ,  A61L31/10 ,  A61L31/148 ,  A61L2300/222 ,  A61L2300/416 ,  A61L2300/45 ,  A61K2300/00

Abstract: A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 μg, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).

Abstract translation: 提供了一种药物递送系统，其包括至少100杯依维莫司和氯倍他索，使得依维莫司与氯倍他索的比例至少为10：1（w / w），依维莫司的重量比为至少10倍 氯倍他索 该系统可以是支架。 还提供了治疗血管的再狭窄或易损斑块的方法，所述方法包括向患者局部施用选自雷帕霉素（西罗莫司），Biolimus A9，deforolimus，AP23572，他克莫司，替西罗莫司，吡美莫司， 40-（2-羟基）乙基雷帕霉素（依维莫司），40-O-（3-羟基）丙基雷帕霉素，40-O- [2-（2-羟基）乙氧基]乙基雷帕霉素，40- O-四唑基雷帕霉素和40-表 - （N1-四唑基）雷帕霉素，并且对患者局部施用由氯倍他索组成的第二药物，其中局部施用的第一药物的最小量为100杯，其中 第二种药物的第一种药物例如为10：1〜100：1（w / w）。

公开(公告)号：US08277436B2

公开(公告)日：2012-10-02

申请号：US12057882

申请日：2008-03-28

Applicant: Wouter Roorda

Inventor： Wouter Roorda

IPC: A61K38/00 ,  C07K14/52 ,  C07K14/515

CPC classification number: A61M25/104 ,  A61K31/198 ,  A61K31/223 ,  A61K31/417 ,  A61K31/557 ,  A61K38/043 ,  A61K38/1725 ,  A61K38/1774 ,  A61K38/1777 ,  A61K38/178 ,  A61K38/1825 ,  A61K38/19 ,  A61M25/0084 ,  A61M2025/0086 ,  A61M2025/0087 ,  A61M2025/105

Abstract: A method of delivering an arteriogenic factor. The factor is delivered in a medically effective manner to structurally enlarge blood vessel. A distal portion of a catheter can be advanced to an existing blood vessel to deliver the arteriogenic factor.

Abstract translation: 递送动脉生成因子的方法。 该因素以医学上有效的方式进行结构扩大血管。 导管的远端部分可以前进到现有血管以递送动脉生成因子。

公开(公告)号：US20080319475A1

公开(公告)日：2008-12-25

申请号：US11767818

申请日：2007-06-25

Applicant: Ian J. Clark ,  Wouter Roorda

Inventor： Ian J. Clark ,  Wouter Roorda

IPC: A61B17/08

CPC classification number: A61B17/0057 ,  A61B17/083 ,  A61B17/10 ,  A61B2017/00637 ,  A61B2017/00668

Abstract: Devices and methods for managing access through tissue is disclosed. The device includes a body. The body is movable from a pre-deployed configuration towards a deployed configuration. The device includes a plurality of tissue engaging portions that extend from the body. At least a portion of the tissue engaging portions are obtuse. At least two of the tissue engaging portions are separated by a first distance in the deployed configuration and a second distance in the pre-deployed configuration. The first distance is smaller than the second distance. The method includes deploying a closure element to tissue adjacent a tissue opening to substantially close the opening following a first procedure. The method also includes selectively opening the opening in the tissue by advancing a distal end of a medical device through the deployed closure element as a part of or before a second procedure.

Abstract translation: 公开了用于管理通过组织进入的装置和方法。 该装置包括一个主体。 身体可以从预部署配置朝向部署配置移动。 该装置包括从身体延伸的多个组织接合部分。 组织接合部分的至少一部分是钝的。 组织接合部分中的至少两个在展开配置中分开第一距离，并且在预部署配置中分开第二距离。 第一距离小于第二距离。 该方法包括将封闭元件部署到邻近组织开口的组织，以在第一程序之后基本上关闭开口。 该方法还包括通过使医疗装置的远端作为第二程序的一部分或之前通过展开的闭合元件前进而选择性地打开组织中的开口。

公开(公告)号：US20060198897A1

公开(公告)日：2006-09-07

申请号：US11213288

申请日：2005-08-26

Applicant: Stephen Pacetti ,  Eugene Michal ,  Syed Hossainy ,  Ni Ding ,  Wouter Roorda

Inventor： Stephen Pacetti ,  Eugene Michal ,  Syed Hossainy ,  Ni Ding ,  Wouter Roorda

IPC: A61K9/50 ,  A61K9/16

CPC classification number: A61K31/727 ,  A61K31/728 ,  A61K31/737 ,  A61L31/10 ,  C08L89/00

Abstract: Coatings for medical devices which include polycationic peptides such as L-arginine and methods for fabricating the coatings are disclosed.